These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 38604018)
1. Discovery of two non-UDP-mimic inhibitors of O-GlcNAc transferase by screening a DNA-encoded library. Balsollier C; Bijkerk S; de Smit A; van Eekelen K; Bozovičar K; Husstege D; Tomašič T; Anderluh M; Pieters RJ Bioorg Chem; 2024 Jun; 147():107321. PubMed ID: 38604018 [TBL] [Abstract][Full Text] [Related]
2. A small molecule that inhibits OGT activity in cells. Ortiz-Meoz RF; Jiang J; Lazarus MB; Orman M; Janetzko J; Fan C; Duveau DY; Tan ZW; Thomas CJ; Walker S ACS Chem Biol; 2015 Jun; 10(6):1392-7. PubMed ID: 25751766 [TBL] [Abstract][Full Text] [Related]
3. O-GlcNAc Transferase: Structural Characteristics, Catalytic Mechanism and Small-Molecule Inhibitors. Ju Kim E Chembiochem; 2020 Nov; 21(21):3026-3035. PubMed ID: 32406185 [TBL] [Abstract][Full Text] [Related]
4. Bisubstrate UDP-peptide conjugates as human O-GlcNAc transferase inhibitors. Borodkin VS; Schimpl M; Gundogdu M; Rafie K; Dorfmueller HC; Robinson DA; van Aalten DM Biochem J; 2014 Feb; 457(3):497-502. PubMed ID: 24256146 [TBL] [Abstract][Full Text] [Related]
5. Bisubstrate Ether-Linked Uridine-Peptide Conjugates as O-GlcNAc Transferase Inhibitors. Makwana V; Ryan P; Malde AK; Anoopkumar-Dukie S; Rudrawar S ChemMedChem; 2021 Feb; 16(3):477-483. PubMed ID: 32991074 [TBL] [Abstract][Full Text] [Related]
7. Structure-Based Evolution of Low Nanomolar O-GlcNAc Transferase Inhibitors. Martin SES; Tan ZW; Itkonen HM; Duveau DY; Paulo JA; Janetzko J; Boutz PL; Törk L; Moss FA; Thomas CJ; Gygi SP; Lazarus MB; Walker S J Am Chem Soc; 2018 Oct; 140(42):13542-13545. PubMed ID: 30285435 [TBL] [Abstract][Full Text] [Related]
8. Versatile O-GlcNAc transferase assay for high-throughput identification of enzyme variants, substrates, and inhibitors. Kim EJ; Abramowitz LK; Bond MR; Love DC; Kang DW; Leucke HF; Kang DW; Ahn JS; Hanover JA Bioconjug Chem; 2014 Jun; 25(6):1025-30. PubMed ID: 24866374 [TBL] [Abstract][Full Text] [Related]
9. Substrate and product analogues as human O-GlcNAc transferase inhibitors. Dorfmueller HC; Borodkin VS; Blair DE; Pathak S; Navratilova I; van Aalten DM Amino Acids; 2011 Mar; 40(3):781-92. PubMed ID: 20640461 [TBL] [Abstract][Full Text] [Related]
10. Antibodies and activity measurements for the detection of O-GlcNAc transferase and assay of its substrate, UDP-GlcNAc. Lefebvre T; Drougat L; Olivier-Van Stichelen S; Michalski JC; Vercoutter-Edouart AS Methods Mol Biol; 2013; 1022():147-59. PubMed ID: 23765660 [TBL] [Abstract][Full Text] [Related]
11. Discovery of O-GlcNAc transferase inhibitors. Gross BJ; Kraybill BC; Walker S J Am Chem Soc; 2005 Oct; 127(42):14588-9. PubMed ID: 16231908 [TBL] [Abstract][Full Text] [Related]
12. Uridine diphosphate release mechanism in O-N-acetylglucosamine (O-GlcNAc) transferase catalysis. She N; Zhao Y; Hao J; Xie S; Wang C Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):609-622. PubMed ID: 30550897 [TBL] [Abstract][Full Text] [Related]
13. Screening oxime libraries by means of mass spectrometry (MS) binding assays: Identification of new highly potent inhibitors to optimized inhibitors γ-aminobutyric acid transporter 1. Kern F; Wanner KT Bioorg Med Chem; 2019 Apr; 27(7):1232-1245. PubMed ID: 30777661 [TBL] [Abstract][Full Text] [Related]
14. O-GlcNAcase: Emerging Mechanism, Substrate Recognition and Small-Molecule Inhibitors. Elbatrawy AA; Kim EJ; Nam G ChemMedChem; 2020 Jul; 15(14):1244-1257. PubMed ID: 32496638 [TBL] [Abstract][Full Text] [Related]
15. O-GlcNAc transferase inhibitors: current tools and future challenges. Trapannone R; Rafie K; van Aalten DM Biochem Soc Trans; 2016 Feb; 44(1):88-93. PubMed ID: 26862193 [TBL] [Abstract][Full Text] [Related]
16. Discovery of small molecule inhibitors of human uridine-cytidine kinase 2 by high-throughput screening. Okesli-Armlovich A; Gupta A; Jimenez M; Auld D; Liu Q; Bassik MC; Khosla C Bioorg Med Chem Lett; 2019 Sep; 29(18):2559-2564. PubMed ID: 31420268 [TBL] [Abstract][Full Text] [Related]
17. Revealing the conformational dynamics of UDP-GlcNAc recognition by O-GlcNAc transferase via Markov state model. Tian J; Dong X; Wu T; Wen P; Liu X; Zhang M; An X; Shi D Int J Biol Macromol; 2024 Jan; 256(Pt 1):128405. PubMed ID: 38016609 [TBL] [Abstract][Full Text] [Related]
18. Discovery of a New Drug-like Series of OGT Inhibitors by Virtual Screening. Loi EM; Tomašič T; Balsollier C; van Eekelen K; Weiss M; Gobec M; Alteen MG; Vocadlo DJ; Pieters RJ; Anderluh M Molecules; 2022 Mar; 27(6):. PubMed ID: 35335358 [No Abstract] [Full Text] [Related]
19. Design of OSMI-4 Analogs Using Scaffold Hopping: Investigating the Importance of the Uridine Mimic in the Binding of OGT Inhibitors. Balsollier C; Tomašič T; Yasini D; Bijkerk S; Anderluh M; Pieters RJ ChemMedChem; 2023 Apr; 18(8):e202300001. PubMed ID: 36752318 [TBL] [Abstract][Full Text] [Related]
20. Optimised chemical synthesis of 5-substituted UDP-sugars and their evaluation as glycosyltransferase inhibitors. Tedaldi LM; Pierce M; Wagner GK Carbohydr Res; 2012 Dec; 364():22-7. PubMed ID: 23147042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]